Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
äŒæ¥ã³ãŒãSMLR
äŒç€ŸåSemler Scientific Inc
äžå Žæ¥Feb 27, 2014
æé«çµå¶è²¬ä»»è
ãCEOãMurphy Chutorian (Douglas)
åŸæ¥å¡æ°79
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Feb 27
æ¬ç€Ÿæåšå°51 E Campbell Ave
éœåžCAMPBELL
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·95008
é»è©±çªå·18777744211
ãŠã§ããµã€ãhttps://www.semlerscientific.com/
äŒæ¥ã³ãŒãSMLR
äžå Žæ¥Feb 27, 2014
æé«çµå¶è²¬ä»»è
ãCEOãMurphy Chutorian (Douglas)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã